Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국
목요일, 9월 03

bioAffinity Technologies Inc

BIAFNASDAQ
Trade with Public
Trade with Public
$9.75
3.1647.95%
가까이에: Sep 1, 5:00 PM EST
$12.82
6.2394.54%
프리마켓: 8:18 AM EST
개요뉴스실적 전망목표가재무심리지분 현황비교주식 보고서

bioAffinity Technologies Earnings & Forecasts

bioAffinity Technologies (BIAF) earnings history, EPS estimates, revenue forecasts and company guidance.

Earnings Per Share (Non-GAAP)

Quarterly Revenue (Billions)

bioAffinity Technologies Guidance

bioAffinity Technologies (BIAF)는 3월 31, 2025에 fiscal year 2025에 대한 가이던스를 마지막으로 발표했습니다. 회사는 해당 기간의 매출을 $6M - $8M 범위로 예상했습니다.

Recent Earnings Results

MetricQ2 '26Q1 '26Q4 '25Q3 '25
Earnings Per Share (Non-GAAP)
Estimate—$-36.00$-40.50$-40.50
Actual$-9.60$-12.15$-16.65$-71.10
Surprise—+66.3%+58.9%-75.6%
Revenue
Estimate—$1.5M$1.4M$1.4M
Actual$1.5M$1.4M$1.6M$1.4M
Surprise—-8.83%+12.9%+2.48%

Earnings & Guidance News

PRO
bioAffinity Technologies Q2 EPS $(0.64) Beats $(2.40) Estimate, Sales $1.511M Beat $1.483M Estimate

bioAffinity Technologies (NASDAQ:BIAF) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(2.40) by 73.33 percent. This is a 87.45 percent increase over losses of $(5.10) per
Benzinga Newsdesk

PRO
bioAffinity Technologies Q1 EPS $(0.81) Beats $(2.70) Estimate, Sales $1.352M Miss $1.553M Estimate

bioAffinity Technologies (NASDAQ:BIAF) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $(2.70) by 70 percent. This is a 83.13 percent increase over losses of $(4.80) per share
Benzinga Newsdesk

PRO
bioAffinity Technologies Reports Q1 CyPath Lung Diagnostic Unit Sales Up 146% YoY

Noninvasive diagnostic continues to gain traction in the current and expanding U.S. addressable market of $3.58 billion for pulmonary nodule management and surveillance of lung cancer survivorsFlow cytometry+AI
Benzinga Newsdesk

PRO
bioAffinity Technologies Q3 EPS $(4.74) Misses $(2.70) Estimate, Sales $1.446M Beat $1.411M Estimate

bioAffinity Technologies (NASDAQ:BIAF) reported quarterly losses of $(4.74) per share which missed the analyst consensus estimate of $(2.70) by 75.56 percent. This is a 1.25 percent increase over losses of $(4.80) per
Benzinga Newsdesk

What's Driving bioAffinity Technologies' Big Pre-Market Surge?

bioAffinity Technologies shares surged over 20% pre-market following a strong third-quarter sales update for its lung cancer diagnostic test.
Mohd Haider

Nasdaq Gains 100 Points; US Consumer Sentiment Falls

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 100 points on Friday. The Dow traded up 0.83% to 46,328.48 while the NASDAQ rose 0.45% to 22,484.92. The S&P 500 also rose, gaining, 0.62% to 6,645.73.
Avi Kapoor

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

Benzinga

Benzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved